In contrast, measuring LDH serum level is a simple and low-cost evaluation that has already been proposed as a biomarker predictive of tumor response/resistance to regorafenib [28], temsirolimus [29], sorafenib [30,31], and anti CTLA-4 mAbs [12] in patients with colorectal, renal, pancreatic cancers, HCC, and melanoma, respectively. This evidence concerns the gene CTLA4 and melanoma.